NCT00616408View on ClinicalTrials.gov

Prediction of Tumor Shrinkage in Acromegaly

CompletedOBSERVATIONAL
Enrollment

61

Participants

Timeline

Start Date

January 31, 1997

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Acromegaly
Interventions
DRUG

Octreotide-LAR

Initial dose is 20 mg every 28 d for three months, then the dose is down-titrated to 10 mg/q28d if GH levels are below 1 ng/ml, up-titrated to 30 mg/q28d if GH levels are above 10 ng/ml and remains to 20 mg/q28 d if GH is between 1-10 ng/ml

Trial Locations (1)

80131

Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Naples

All Listed Sponsors
lead

Federico II University

OTHER

NCT00616408 - Prediction of Tumor Shrinkage in Acromegaly | Biotech Hunter | Biotech Hunter